Dr. Reddy's Laboratories (DRL) will host a conference call for investors and financial analysts to discuss the current developments that follows the US Food and Drug Administration (US FDA) rejection of the claims of DRL for 180-day marketing exclusivity for Omeprazole 40 mg capsules in the US market. The share value of the company had reportedly seen lot of negative fluctuations during the days that followed the US FDA announcement.
According to an official release, the Conference Call is slated for 3 PM IST, Thursday, November 22, 2001. The Dial-in numbers - From Bangalore: 933 5414*/ 228 8180* Outside Bangalore, within India: 080 933 5414*/ 080 228 8180* Participants outside India: (80) 238 8910 / (80) 228 8180 have also been announced by the company.
The release stated that no password/pin number is necessary to dial in to any of the calls. The participation in the call is limited to 90 and the registration will be on the first-come- first-serve basis. The operator will provide instructions on asking questions before and during the call.
The live audio webcast of the conference call will be available at www.drreddys.com. The transcripts of the conference call/webcast will also be available on the Company's website within 72 hours of the Conference Call, the release said.